Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.857,06
0,19%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Rexahn Pharmaceuticals Inc (REXN) Rexahn Pharmaceuticals Inc (REXN) Notizie

REXN

Rexahn Pharmaceuticals (REXN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REXN
DataOraFonteTitoloSimboloCompagnia
14/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REXNRexahn Pharmaceuticals Inc
09/06/202300:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REXNRexahn Pharmaceuticals Inc
15/05/202314:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:REXNRexahn Pharmaceuticals Inc
01/05/202322:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:REXNRexahn Pharmaceuticals Inc
01/05/202322:13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:REXNRexahn Pharmaceuticals Inc
05/04/202323:05Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/03/202323:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:REXNRexahn Pharmaceuticals Inc
14/02/202320:04Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:REXNRexahn Pharmaceuticals Inc
10/06/202222:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REXNRexahn Pharmaceuticals Inc
17/05/202222:38Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:REXNRexahn Pharmaceuticals Inc
14/02/202222:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
09/06/202123:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:REXNRexahn Pharmaceuticals Inc
07/06/202122:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:REXNRexahn Pharmaceuticals Inc
07/06/202122:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
16/02/202112:31Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:REXNRexahn Pharmaceuticals Inc
11/02/202122:44Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
04/02/202113:28Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/11/202021:44Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:REXNRexahn Pharmaceuticals Inc
10/11/202016:09GlobeNewswire Inc.Ocuphire to Participate in Upcoming Virtual HCW Conference in NovemberNASDAQ:REXNRexahn Pharmaceuticals Inc
05/11/202017:50GlobeNewswire Inc.Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire PharmaNASDAQ:REXNRexahn Pharmaceuticals Inc
02/11/202015:00GlobeNewswire Inc.Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire PharmaNASDAQ:REXNRexahn Pharmaceuticals Inc
20/10/202014:56Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:REXNRexahn Pharmaceuticals Inc
02/10/202015:27Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/09/202015:19Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
25/07/202003:21PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Reminds DCOM and REXN Shareholders About Its Ongoing InvestigationsNASDAQ:REXNRexahn Pharmaceuticals Inc
17/07/202021:15PR Newswire (US)INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are ...NASDAQ:REXNRexahn Pharmaceuticals Inc
08/07/202003:07PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Reminds REXN and DLMV Shareholders About Its Ongoing InvestigationsNASDAQ:REXNRexahn Pharmaceuticals Inc
06/07/202022:09Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:REXNRexahn Pharmaceuticals Inc
29/06/202022:47PR Newswire (US)Rexahn Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Rexahn Pharmaceuticals, Inc....NASDAQ:REXNRexahn Pharmaceuticals Inc
27/06/202003:03PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Rexahn Pharmaceuticals, Inc.NASDAQ:REXNRexahn Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:REXN

La tua Cronologia

NASDAQ
ZAAYKX
Access Holdings Fund I
NASDAQ
GESVX
Goldman Sachs Enhanced I...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network